Business Wire

MI-EATON

23.9.2021 12:32:11 CEST | Business Wire | Press release

Share
Eaton Introduces Zero-Leak Compact Combo Valve to Manage Harmful Fuel Vapors and Meet Upcoming Regulations

Power management company Eaton today announced its Vehicle Group has introduced a new zero-leak Compact Combo Valve that safely vents harmful evaporative fuel vapors in the tank by stacking a Fill Limit Vent Valve (FLVV) and a new Zero-Leak Grade Vent Valve (GVV).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005077/en/

A key benefit of the Compact Combo is reduced fuel vapor permeation. The smaller footprint of the stacked valves allows for a tighter seal when welded to the tank, in turn reducing permeation.

This innovative configuration reduces the product’s footprint by 20 mm, which decreases potential leak paths and provides fuel tank manufacturers more design flexibility. The Zero-Leak GVV fulfills all government-mandated requirements for zero-leak vapor valves.

“Eaton's world-class engineering teams are leading the way in developing innovative and highly efficient fuel vapor management products,” said Brian Contat, business unit director, Fuel Emissions, Eaton’s Vehicle Group. “As evaporative emissions reduction and vehicle standards become more stringent, Eaton’s fuel emissions products deliver a competitive advantage worldwide that helps our customers achieve or exceed upcoming emissions regulations.”

New Compact Combo technology reduces hydrocarbon emissions during refueling

The new Compact Combo Valve technology reduces hydrocarbon emissions with 98 percent efficiency during the vehicle refueling process and allows manufacturers to meet vehicle hydrocarbon emissions standards while the vehicle is parked.

The Compact Combo Valve has several unique design features that increase valve functionality to meet both tank and customer requirements. These features include a seal that reduces liquid leak in static venting conditions, as well as the ability to change the shut-off height of the FLVV through component substitution. Eaton also offers an added slosh baffle feature for vehicle applications involving aggressive driving dynamics that may cause shifting liquid fuel to leak.

“We can use short or long FLVV housings, depending on the application, for maximum permeation reduction,” Contat said. “We are able to cover all shut-off height requirements to vent above the shut-off valve when the main refueling valve is closed and the GVV shut-off height remains constant and optimized.”

Zero-Leak GVV prevents fuel leakage in all conditions

The GVV’s position at the top of the fuel tank prevents liquid leakage during all situations, including when the vehicle is traveling or parked at an angle. This is an added benefit when compared with competitive technologies that do not allow optimized positioning within the fuel tank during such conditions.

“Our design gives customers greater freedom to perform grade venting, which allows manufacturers to meet zero-leak vapor valve requirements,” Contat said. “You have to ensure you’re venting during all normal vehicle operations and degrees of parking.”

The zero-leak vapor valve requirement is an industry requisite to meet vehicle safety, driveability, emissions and component durability specifications. Eaton’s new Zero-Leak GVV sealing methodology employs an elastomeric seal over-molded onto a substrate to ensure this requirement is met.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye